跳至主要内容
临床试验/NCT04118946
NCT04118946Unknown1 期

Intra Vesical Instillation Versus Submucosal Injection of Platelet Enriched Plasma for Treatment of Interstitial Cystitis/Bladder Pain Syndrome: A Randomized Controlled Trial

Mansoura University1 个研究点 分布在 1 个国家目标入组 33 人开始时间: 2019年3月20日最近更新:
适应症
干预措施

试验速览

阶段
1 期
入组人数
33
试验地点
1
主要终点
efficacy as measured by global response assessment "GRA"

研究概览

简要总结

A prospective randomized trial will be conducted aiming at evaluation the efficacy and safety of platelet enriched plasma for management of bladder pain syndrome .

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Patients with a diagnosis of interstitial cystitis/ Bladder painful Syndrome for more than 3 months will be enrolled

排除标准

  • Patients with Anemia, blood disorders, history of pelvic irradiation, pelvic malignancy, and active urinary tract infection unless treated, vesical stone, gynecological disorders e.g. uterine fibroid and neurological disorders will be excluded. Patients less than 18 years old will not be allowed to participate.

研究组 & 干预措施

intravesical instillation

Active Comparator

Intravesical instillation of platelet enriched plasma every week for 6 weeks

干预措施: platelet enriched plasma (Biological)

submucosal injection

Active Comparator

submucosal injectionof platelet enriched plasma

干预措施: platelet enriched plasma (Biological)

结局指标

主要结局

efficacy as measured by global response assessment "GRA"

时间窗: 3 month for each case. Expected time about 18-24 months for whole study period

It will be measured by global response assessment as main tool. Other measurable outcomes including visual analogue scale for pain, Interstitial Cystitis Symptom Index (4 questions) and Problem Index (4 questions) (ICSI/ICPI). These measures will be collected after each session during period of administration of treatment then at 3 months after end of treatment

次要结局

  • safety : rate of complication and grade of complications graded by Dindo-Clavien classification(3 month for each case. Expected time about 18-24 months for whole study period)
  • incidence of urinary tract infection and gynecological infection among this group(3 month for each case. Expected time about 18-24 months for whole study period)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Ahmed Sobhy Elhefnawy

principle investigator

Mansoura University

研究点 (1)

Loading locations...

相似试验